332 related articles for article (PubMed ID: 33683917)
21. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma.
Ma MCJ; Tadros S; Bouska A; Heavican T; Yang H; Deng Q; Moore D; Akhter A; Hartert K; Jain N; Showell J; Ghosh S; Street L; Davidson M; Carey C; Tobin J; Perumal D; Vose JM; Lunning MA; Sohani AR; Chen BJ; Buckley S; Nastoupil LJ; Davis RE; Westin JR; Fowler NH; Parekh S; Gandhi M; Neelapu S; Stewart D; Bhalla K; Iqbal J; Greiner T; Rodig SJ; Mansoor A; Green MR
Haematologica; 2022 Mar; 107(3):690-701. PubMed ID: 33792219
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Rogers KA; Andritsos LA; Wei L; McLaughlin EM; Ruppert AS; Anghelina M; Blachly JS; Call T; Chihara D; Dauki A; Guo L; Ivy SP; James LR; Jones D; Kreitman RJ; Lozanski G; Lucas DM; Ngankeu A; Phelps M; Ravandi F; Schiffer CA; Carson WE; Jones JA; Grever MR
Blood; 2021 Jun; 137(25):3473-3483. PubMed ID: 33754642
[TBL] [Abstract][Full Text] [Related]
23. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
Valero JG; Matas-Céspedes A; Arenas F; Rodriguez V; Carreras J; Serrat N; Guerrero-Hernández M; Yahiaoui A; Balagué O; Martin S; Capdevila C; Hernández L; Magnano L; Rivas-Delgado A; Tannheimer S; Cid MC; Campo E; López-Guillermo A; Colomer D; Pérez-Galán P
Leukemia; 2021 Sep; 35(9):2635-2649. PubMed ID: 33731849
[TBL] [Abstract][Full Text] [Related]
24. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Merryman RW; Redd RA; Nishihori T; Chavez J; Nieto Y; Darrah JM; Rao U; Byrne MT; Bond DA; Maddocks KJ; Spinner MA; Advani RH; Ballard HJ; Svoboda J; Singh AK; McGuirk JP; Modi D; Ramchandren R; Romancik J; Cohen JB; Frigault MJ; Chen YB; Serritella AV; Kline J; Ansell S; Nathan S; Rahimian M; Joyce RM; Shah M; David KA; Park S; Beaven AW; Habib A; Bachanova V; Nakhoda S; Khan N; Lynch RC; Smith SD; Ho VT; LaCasce A; Armand P; Herrera AF
Blood Adv; 2021 Mar; 5(6):1648-1659. PubMed ID: 33710337
[TBL] [Abstract][Full Text] [Related]
25. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
Rhodes JM; Mato AR
Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
[TBL] [Abstract][Full Text] [Related]
26. How should we use ibrutinib in patients with mantle cell lymphoma?
Jerkeman M
Br J Haematol; 2021 May; 193(3):445-446. PubMed ID: 33694156
[No Abstract] [Full Text] [Related]
27. Molecular biology of Hodgkin lymphoma.
Weniger MA; Küppers R
Leukemia; 2021 Apr; 35(4):968-981. PubMed ID: 33686198
[TBL] [Abstract][Full Text] [Related]
28. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
29. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
Garcia-Manero G; Santini V; Almeida A; Platzbecker U; Jonasova A; Silverman LR; Falantes J; Reda G; Buccisano F; Fenaux P; Buckstein R; Diez Campelo M; Larsen S; Valcarcel D; Vyas P; Giai V; Olíva EN; Shortt J; Niederwieser D; Mittelman M; Fianchi L; La Torre I; Zhong J; Laille E; Lopes de Menezes D; Skikne B; Beach CL; Giagounidis A
J Clin Oncol; 2021 May; 39(13):1426-1436. PubMed ID: 33764805
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
Casulo C; Dixon JG; Ou FS; Hoster E; Peterson BA; Hochster HS; Brice P; Ladetto M; Hiddemann W; Marcus R; Kimby E; Herold M; Nielsen T; Morschhauser F; Rummel M; Hagenbeek A; Vitolo U; Salles GA; Shi Q; Flowers CR
Blood Adv; 2021 Mar; 5(6):1737-1745. PubMed ID: 33749762
[TBL] [Abstract][Full Text] [Related]
32. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Davids MS; O'Connor OA; Jurczak W; Samaniego F; Fenske TS; Zinzani PL; Patel MR; Ghosh N; Cheson BD; Derenzini E; Brander DM; Reeves JA; Knopińska-Posłuszny W; Allan JN; Phillips T; Caimi PF; Lech-Maranda E; Burke JM; Agajanian R; Pettengell R; Leslie LA; Cheah CY; Fonseca G; Essell J; Chavez JC; Pagel JM; Sharman JP; Hsu Y; Miskin HP; Sportelli P; Weiss MS; Flinn IW
Blood Adv; 2021 Dec; 5(23):5332-5343. PubMed ID: 34547767
[TBL] [Abstract][Full Text] [Related]
33. PI3Kδ-CK1ε Inhibitor Umbralisib Shows Promise in R/R Indolent NHL.
Cancer Discov; 2021 May; 11(5):1005. PubMed ID: 33741708
[TBL] [Abstract][Full Text] [Related]
34. Targeted Therapies for Follicular Lymphoma.
Girard J; Karimi Y; Carty S; Wilcox R; Kaminiski M; Malek S; Phillips T
Curr Hematol Malig Rep; 2021 Feb; 16(1):25-31. PubMed ID: 33754292
[TBL] [Abstract][Full Text] [Related]
35. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E;
Lancet Oncol; 2021 May; 22(5):620-631. PubMed ID: 33743851
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
[TBL] [Abstract][Full Text] [Related]
37. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.
Tiacci E; De Carolis L; Simonetti E; Merluzzi M; Bennati A; Perriello VM; Pucciarini A; Santi A; Venanzi A; Pettirossi V; Schiavoni G; Tasselli L; Ascani S; Volpetti S; Falini B
Leukemia; 2021 Nov; 35(11):3314-3318. PubMed ID: 33731847
[No Abstract] [Full Text] [Related]
39. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.
Reville PK; Kantarjian HM; Ravandi F; Jabbour E; DiNardo CD; Daver N; Pemmaraju N; Ohanian M; Alvarado Y; Xiao L; Alatrash G; Loghavi S; Rausch CR; Borthakur G; Konopleva M; Cortes J; Kadia TM
Blood Cancer J; 2021 Mar; 11(3):60. PubMed ID: 33731681
[No Abstract] [Full Text] [Related]
40. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
